乳腺导管原位癌中肿瘤浸润淋巴细胞的患病率及临床相关性
该研究在1488例连续乳腺导管原位癌(DCIS)女性中评估肿瘤浸润淋巴细胞(TILs)的患病率及临床相关性,中位随访8.2年。TILs在Her-2阳性DCIS中更常见,但TILs与同侧乳腺事件(IBE)风险无显著关联。作者认为数据提示部分DCIS患者可考虑免疫治疗。
要点
- 1488例DCIS中,35.1%间质TILs<1%,58.3%为1-49%,6.5%≥50%。
- TILs评估的观察者间一致性ICC为0.96(95%CI 0.95-0.97)。
- TILs与10年IBE累积发生率无显著关联(19% vs 17.3% vs 18.7%,P=0.767)。
核心结论
- TILs在Her-2阳性DCIS中更常见,但TILs与10年IBE风险无显著关联,数据提示部分DCIS患者可考虑免疫治疗。
研究设计与样本
- 研究纳入1488例连续DCIS女性,中位随访8.2年,TILs评估标准由国际免疫肿瘤生物标志物工作组预先定义。
主要发现
- 1488例DCIS中,35.1%间质TILs<1%,58.3%为1-49%,6.5%≥50%。
- TILs评估的观察者间一致性ICC为0.96(95%CI 0.95-0.97)。
- Her-2阳性DCIS中TILs≥50%者占24%,三阴性占11%,Luminal B/Her-2阳性占9%,Luminal A/B占1%(P<0.0001)。
- 按TILs百分比分层(<1%、1-49.9%、≥50%),10年IBE累积发生率分别为19%、17.3%、18.7%(P=0.767)。
关键数值与推荐
- TILs以连续变量和分类变量分析,分类阈值为<1%、1-49.9%、≥50%。
- 与TILs显著相关的临床因素包括内在亚型、分级、坏死、手术类型(P≤0.001)。
临床怎么用
- 作者认为数据提示部分DCIS患者可考虑免疫治疗。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Tumor-infiltrating lymphocytes (TILs) are a robust prognostic adjunct in invasive breast cancer, but their clinical role in ductal carcinoma in situ (DCIS) has not been ascertained. PATIENTS AND METHODS: We evaluated the prevalence and clinical relevance of TILs in a well annotated series of 1488 consecutive DCIS women with a median follow-up of 8.2 years. Detailed criteria for TILs evaluation were pre-defined involving the International Immuno-Oncology Biomarker Working Group. TILs percentage was considered both as a continuous and categorical variable. Levels of TILs were examined for their associations with ipsilateral breast event (IBE), whether in situ or invasive. RESULTS: Of the 1488 patients with DCIS under study, 35.1% had <1%, 58.3% 1-49% and 6.5% ≥50% peri-ductal stromal lymphocytes. The interobserver agreement in TILs evaluation, measured by the intraclass correlation coefficient (ICC) was 0.96 (95% CI 0.95-0.97). At univariable analysis, clinical factors significantly associated with TILs (P ≤0.001) were intrinsic subtype, grade, necrosis, type of surgery. Her-2 positive DCIS were more frequently associated with TILs (24% of patients with TILs ≥50%), followed by the triple negative (11%), Luminal B/Her-2 positive (9%) and Luminal A/B subtypes (1%) (P < 0.0001). We did not find any association between TILs as a continuous variable and the risk of IBEs. Likewise, when patients were stratified by TILs percentage (<1%, between 1% and 49.9%, and ≥50%), no statistically significant association was observed (10-year cumulative incidence of IBEs: 19%, 17.3%, and 18.7% respectively, P = 0.767). CONCLUSION: TILs occur more frequently in the Her-2 positive DCIS. Although we did not find a significant association between TILs and the 10-year risk of IBE, our data suggest that immunotherapies might be considered in subsets of DCIS patients.
引用
- Pruneri G, Lazzeroni M, Bagnardi V, et al. The prevalence and clinical relevance of tumor-infiltrating lymphocytes (TILs) in ductal carcinoma in situ of the breast. Ann Oncol. 2017. PMID: 28426105. doi:10.1093/annonc/mdw623
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。